Jazz Pharmaceuticals to Acquire Gentium for $57.00/Share

Jazz Pharmaceuticals plc JAZZ and Gentium S.p.A. GENT today announced that they have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, in a transaction that is valued at approximately $1 billion. Gentium is a biopharmaceutical company focused on the development and manufacturing of therapies to treat and prevent a variety of rare diseases and conditions that currently have few or no treatment options, including orphan vascular diseases related to cancer treatments.  In October 2013, the European Commission granted marketing authorization for Defitelio™ (defibrotide), the See full press release